Prevention of tuberculosis in rhesus macaques by a cytomegalovirus-based vaccine

• Published in: Nature medicine Vol. 24; no. 2; pp. 130 - 143
• Main Authors: Hansen, Scott G, Zak, Daniel E, Xu, Guangwu, Ford, Julia C, Marshall, Emily E, Malouli, Daniel, Gilbride, Roxanne M, Hughes, Colette M, Ventura, Abigail B, Ainslie, Emily, Randall, Kurt T, Selseth, Andrea N, Rundstrom, Parker, Herlache, Lauren, Lewis, Matthew S, Park, Haesun, Planer, Shannon L, Turner, John M, Fischer, Miranda, Armstrong, Christina, Zweig, Robert C, Valvo, Joseph, Braun, Jackie M, Shankar, Smitha, Lu, Lenette, Sylwester, Andrew W, Legasse, Alfred W, Messerle, Martin, Jarvis, Michael A, Amon, Lynn M, Aderem, Alan, Alter, Galit, Laddy, Dominick J, Stone, Michele, Bonavia, Aurelio, Evans, Thomas G, Axthelm, Michael K, Früh, Klaus, Edlefsen, Paul T, Picker, Louis J
• Format: Journal Article
• Language: English
• Published: United States Nature Publishing Group 01.02.2018
• Subjects: Animals; Antigens; Bacillus Calmette-Guerin vaccine; BCG; BCG Vaccine - immunology; CD4 antigen; CD8 antigen; Cell culture; Computed tomography; Cytomegalovirus; Cytomegalovirus - immunology; Disease control; Disease prevention; Immunization; Immunological memory; Infections; Inserts; Lymphocytes; Lymphocytes T; Macaca mulatta - immunology; Memory cells; Monkeys & apes; Mycobacterium tuberculosis; Mycobacterium tuberculosis - immunology; Necropsy; Tuberculosis; Tuberculosis - immunology; Vaccination; Vaccines
• ISSN: 1078-8956; 1546-170X
• DOI: 10.1038/nm.4473

Despite widespread use of the bacille Calmette-Guérin (BCG) vaccine, tuberculosis (TB) remains a leading cause of global mortality from a single infectious agent (Mycobacterium tuberculosis or Mtb). Here, over two independent Mtb challenge studies, we demonstrate that subcutaneous vaccination of rhesus macaques (RMs) with rhesus cytomegalovirus vectors encoding Mtb antigen inserts (hereafter referred to as RhCMV/TB)-which elicit and maintain highly effector-differentiated, circulating and tissue-resident Mtb-specific CD4 and CD8 memory T cell responses-can reduce the overall (pulmonary and extrapulmonary) extent of Mtb infection and disease by 68%, as compared to that in unvaccinated controls, after intrabronchial challenge with the Erdman strain of Mtb at ∼1 year after the first vaccination. Fourteen of 34 RhCMV/TB-vaccinated RMs (41%) across both studies showed no TB disease by computed tomography scans or at necropsy after challenge (as compared to 0 of 17 unvaccinated controls), and ten of these RMs were Mtb-culture-negative for all tissues, an exceptional long-term vaccine effect in the RM challenge model with the Erdman strain of Mtb. These results suggest that complete vaccine-mediated immune control of highly pathogenic Mtb is possible if immune effector responses can intercept Mtb infection at its earliest stages.